GlassScriptPhysician profile
Carroll Alexander Pinner
NPI 1275515108
$20,316.50
in general payments reported to CMS, 2019-2025
73 companies · $2,840 in 2025
The $2,840 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,087 · 2020: $2,682 · 2021: $3,389 · 2022: $2,983 · 2023: $2,852 · 2024: $2,483 · 2025: $2,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,143 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,143.15 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,793.58 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,729.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,604.43 | 2021-2025 | |
| Amgen INC. | $1,517.69 | 2019-2024 | Repatha, Prolia, Evenity |
| Lilly USA, LLC | $928.63 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $812.56 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $788.47 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $756.91 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $753.54 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $744.15 | 2019-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $728.81 | 2020-2025 | Rexulti |
| Pfizer INC. | $645.13 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $537.13 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $481.91 | 2019-2023 | |
| Glaxosmithkline, LLC. | $478.00 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $349.00 | 2020-2025 | Rexulti, Vyepti |
| Corcept Therapeutics | $346.29 | 2021-2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $343.88 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $343.28 | 2023-2025 | Sunosi, Auvelity |
| Esperion Therapeutics, INC. | $275.87 | 2021-2025 | Nexletol |
| Xeris Pharmaceuticals, INC. | $254.51 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $245.96 | 2024-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $242.60 | 2019-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $229.17 | 2019-2024 | Xarelto |
| Eisai INC. | $227.03 | 2020-2024 | |
| Allergan, INC. | $209.98 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $195.39 | 2019-2022 | |
| Astellas Pharma US INC | $188.07 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $184.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $168.53 | 2020-2025 | Zoryve, Livalo |
| Dexcom, INC. | $165.87 | 2023-2025 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $149.37 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $146.13 | 2020-2021 | |
| Abbott Laboratories | $131.28 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Ardelyx, INC. | $129.65 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $120.55 | 2019-2021 | |
| Mylan Specialty L.P. | $119.80 | 2019-2022 | |
| Daiichi Sankyo INC. | $116.70 | 2019-2023 | Injectafer |
| Forte Bio-Pharma LLC | $87.16 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $76.38 | 2020-2025 | Fanapt, Hetlioz |
| Nestle Healthcare Nutrition INC. | $75.35 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $69.51 | 2022 | |
| Intuitive Surgical, INC. | $66.67 | 2019 | |
| Braintree Laboratories, INC. | $53.32 | 2019 | |
| Phathom Pharmaceuticals, INC. | $53.00 | 2023-2025 | Voquezna |
| Azurity Pharmaceuticals, INC. | $48.94 | 2024-2025 | Horizant, Azmiro, Alvesco |
| Supernus Pharmaceuticals, INC. | $46.83 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $45.50 | 2019-2021 | |
| Impel Pharmaceuticals INC. | $42.57 | 2023 | Trudhesa |
| Medtronic, INC. | $34.05 | 2023 | Intellis Adaptivestim |
| Genzyme Corporation | $33.96 | 2024 | |
| Shield Therapeutics INC | $33.41 | 2025 | |
| Vivus LLC | $29.87 | 2020 | |
| Scynexis, INC. | $29.57 | 2022 | |
| Boston Scientific Corporation | $25.01 | 2023 | Wavewriter Alpha Prime 16 |
| Jazz Pharmaceuticals INC. | $24.85 | 2021 | |
| Mannkind Corporation | $22.38 | 2022 | |
| Genentech USA, INC. | $18.88 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $18.76 | 2022 | |
| Tris Pharma INC | $18.49 | 2024 | Dyanavel Xr |
| Cvrx, INC. | $17.60 | 2024 | Barostim Neo System |
| Sunovion Pharmaceuticals INC. | $17.03 | 2020 | |
| Alnylam Pharmaceuticals INC. | $16.92 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $13.94 | 2021 | |
| Intuity Medical INC | $13.42 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Medicure Pharma INC. | $13.40 | 2022 | |
| Bausch Health US, LLC | $12.97 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.83 | 2023 | Quviviq |
| Insulet Corporation | $12.81 | 2021 | |
| Acerus Pharmaceuticals Corporation | $12.51 | 2022 | |
| Organon LLC | $11.99 | 2025 | Nexplanon |
| Hikma Pharmaceuticals USA | $11.98 | 2021 | |
| Alfasigma USA, INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carroll Pinner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.